Compare · RMD vs SIBN
RMD vs SIBN
Side-by-side comparison of ResMed Inc. (RMD) and SI-BONE Inc. (SIBN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both RMD and SIBN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $28.02B, about 42.2x SIBN ($663.9M).
- Over the past year, RMD is down 23.1% and SIBN is down 20.6% - SIBN leads by 2.4 points.
- SIBN has been more active in the news (11 items in the past 4 weeks vs 6 for RMD).
- RMD has more recent analyst coverage (25 ratings vs 11 for SIBN).
- Company
- ResMed Inc.
- SI-BONE Inc.
- Price
- -
- -
- Market cap
- $28.02B
- $663.9M
- 1M return
- -6.57%
- +15.60%
- 1Y return
- -23.07%
- -20.63%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2018
- News (4w)
- 6
- 11
- Recent ratings
- 25
- 11
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
SI-BONE Inc.
SI-BONE, Inc., a medical device company, develops implantable devices used in the surgical treatment of the sacropelvic anatomy in the United States and Internationally. The company offers iFuse, a minimally invasive surgical implant system, which is intended to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.
Latest RMD
- Global General Counsel Rider Michael J covered exercise/tax liability with 269 units of ResMed Common Stock, decreasing direct ownership by 3% to 9,488 units (SEC Form 4) (tax withholding)
- Angelini Ventures Marks First Portfolio Company Exit as ResMed Acquires Noctrix Health for $340 million
- Resmed Completes Acquisition of Noctrix Health, Expanding Clinical Sleep Health Portfolio
- SEC Form SD filed by ResMed Inc.
- Resmed Announces Participation in the 46th Annual William Blair Growth Stock Conference
- Resmed and ŌURA Partner to Expand Access to Sleep Health Education and Care
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $1,037,233 worth of ResMed Common Stock (4,991 units at $207.82) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 3 filed by new insider Bloomer Aaron
- SEC Form 4 filed by Chief Financial Officer Sandercock Brett
- SEC Form 8-K filed by ResMed Inc.
Latest SIBN
- Director Dunn Jeffrey W was granted 10,957 shares and sold $54,505 worth of shares (3,575 units at $15.25), increasing direct ownership by 75% to 16,057 units (SEC Form 4) to cover withholding tax
- Director Nishimura Mika was granted 10,957 shares, increasing direct ownership by 33% to 43,673 units (SEC Form 4)
- Director West Thomas A. was granted 10,957 shares, increasing direct ownership by 41% to 37,947 units (SEC Form 4)
- Director Freund John Gordon was granted 10,957 shares, increasing direct ownership by 25% to 54,258 units (SEC Form 4)
- Director Davis Timothy E Jr was granted 10,957 shares, increasing direct ownership by 17% to 76,679 units (SEC Form 4)
- SI-BONE Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- SI-BONE To Present at Truist Securities 2026 MedTech Conference on June 16, 2026
- Director Davis Timothy E Jr exercised 12,064 shares at a strike of $4.32 and sold $104,187 worth of shares (7,280 units at $14.31), increasing direct ownership by 8% to 65,722 units (SEC Form 4)
- Chief Executive Officer Francis Laura sold $220,000 worth of shares (14,957 units at $14.71), decreasing direct ownership by 8% to 503,444 units (SEC Form 4) to cover withholding tax
- SVP, Ops & Adm/Chief Legal Ofr Pisetsky Michael A. sold $54,527 worth of shares (3,726 units at $14.63), decreasing direct ownership by 0.82% to 280,509 units (SEC Form 4) (tax liability)